BTLSB Stock Overview
An agricultural technology company, discovers and develops novel biological products in Belgium and internationally. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biotalys NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.09 |
52 Week High | €0 |
52 Week Low | €0 |
Beta | 0.93 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -55.86% |
Recent News & Updates
Recent updates
Shareholder Returns
BTLSB | GB Chemicals | GB Market | |
---|---|---|---|
7D | 0% | -3.9% | -2.6% |
1Y | n/a | -25.8% | 2.7% |
Return vs Industry: Insufficient data to determine how BTLSB performed against the UK Chemicals industry.
Return vs Market: Insufficient data to determine how BTLSB performed against the UK Market.
Price Volatility
BTLSB volatility | |
---|---|
BTLSB Average Weekly Movement | n/a |
Chemicals Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 10.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BTLSB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTLSB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 75 | Kevin Helash | www.biotalys.com |
Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and anthracnose in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; and BIOFUN-4 targeting oomycetes in fruits and vegetables.
Biotalys NV Fundamentals Summary
BTLSB fundamental statistics | |
---|---|
Market cap | €87.15m |
Earnings (TTM) | -€20.51m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs BTLSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BTLSB income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €20.51m |
Earnings | -€20.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | -0.64 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 11.3% |
How did BTLSB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/06/30 17:24 |
End of Day Share Price | 2024/04/02 00:00 |
Earnings | 2023/12/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biotalys NV is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Sebastian Bray | Berenberg |
Guy Sips | KBC Securities NV |
Thomas Vranken | KBC Securities NV |